Literature DB >> 16101515

Transcriptionally targeted adenovirus vectors.

Hamid Sadeghi1, Mary M Hitt.   

Abstract

Adenovirus vectors are the most highly efficient vehicles currently available for gene transfer to mammalian cells. Their ability to transduce both proliferating and non-dividing cells allows in vivo gene delivery, but the wide spectrum of cell types infected by adenovirus necessitates a requirement for targeting, particularly if the transduced gene is detrimental when expressed in inappropriate tissues. Over the past decade, numerous investigators have examined tissue- or tumor-specific enhancer-promoters as a means to transcriptionally target genes delivered by adenovirus vectors. We review here recent developments in adenovirus vectors including improvements in the vector backbone to maintain promoter specificity. In addition, we discuss the regulatory elements directing cell-specific expression of genes encoding telomerase, prostate-specific antigen, probasin, osteocalcin, tyrosinase, alpha-fetoprotein, surfactant B, and mammaglobin. Recent results using these regulatory sequences to target Ad vectors to cancer cells are highlighted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16101515     DOI: 10.2174/1566523054546189

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  21 in total

Review 1.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

2.  Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences.

Authors:  S Chaurasiya; P Hew; P Crosley; D Sharon; K Potts; K Agopsowicz; M Long; C Shi; M M Hitt
Journal:  Cancer Gene Ther       Date:  2016-05-06       Impact factor: 5.987

Review 3.  Gene therapy for cancer treatment: past, present and future.

Authors:  Deanna Cross; James K Burmester
Journal:  Clin Med Res       Date:  2006-09

4.  Adenoviral insulinoma-associated protein 1 promoter-driven suicide gene therapy with enhanced selectivity for treatment of neuroendocrine cancers.

Authors:  Victoria Akerstrom; Chiachen Chen; Michael S Lan; Mary B Breslin
Journal:  Ochsner J       Date:  2013

5.  Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.

Authors:  Alessandra Curioni Fontecedro; Verena Lutschg; Ossia Eichhoff; Reinhard Dummer; Urs F Greber; Silvio Hemmi
Journal:  Virol J       Date:  2010-07-29       Impact factor: 4.099

6.  hTERT and BIRC5 gene promoters for cancer gene therapy: A comparative study.

Authors:  Mikhail V Shepelev; Eugene P Kopantzev; Tatiana V Vinogradova; Eugene D Sverdlov; Igor V Korobko
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

7.  Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy.

Authors:  Sunetra Ray; Ramasamy Paulmurugan; Manish R Patel; Byeong C Ahn; Lily Wu; Michael Carey; Sanjiv S Gambhir
Journal:  Mol Ther       Date:  2008-09-02       Impact factor: 11.454

8.  Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer.

Authors:  Jeremy B Burton; Mai Johnson; Makoto Sato; Sok Boon S Koh; David J Mulholland; David Stout; Arion F Chatziioannou; Michael E Phelps; Hong Wu; Lily Wu
Journal:  Nat Med       Date:  2008-07-11       Impact factor: 53.440

9.  Selective killing of Smad4-negative tumor cells via a designed repressor strategy.

Authors:  Vidula Dixit; Rudy L Juliano
Journal:  Mol Pharmacol       Date:  2008-04-21       Impact factor: 4.436

10.  Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines.

Authors:  Hai-tao Meng; Lu Li; Hui Liu; Ying Wang; Gong-chu Li; Wen-bin Qian
Journal:  Acta Pharmacol Sin       Date:  2009-10-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.